I.CERAM, specialist in innovative biocompatible ceramic implants, is implementing its innovation plan to finalize the obtaining of CE – MDR markings by setting up a strategic financing envelope of 1.4 million euros allowing cope with the delay and the increased costs of notified bodies.
This financing package consists of the issue, for a maximum of 1 million euros, of bonds convertible into new shares or to be issued with share subscription warrants to Alpha Blue Ocean (ABO) and a grant of 0.4 million euros from BPI France as part of the I.Nov project. It will allow I.Ceram to ensure the continuity of its latest clinical and pre-clinical studies, made obligatory by the new MDR regulations for the marketing of its implants loaded with antibiotics.